Benjamin D. Hopkins
YOU?
Author Swipe
View article: Unlocking the therapeutic potential of rigosertib as a selective therapy for ovarian cancer
Unlocking the therapeutic potential of rigosertib as a selective therapy for ovarian cancer Open
Precision oncology seeks to exploit tumor-specific drug sensitivities. Traditionally, this is accomplished through the identification and targeting of highly recurrent mutations. This paradigm falls short in ovarian cancer where the oncoge…
View article: Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kα potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models
Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kα potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models Open
Background While PI3K/AKT/mTOR signalling plays a critical role in cancer, targeting this pathway with single node inhibitors has limited efficacy due to several known factors such as pathway feedback reactivation, co-occurring pathway mut…
View article: Epigenomic analysis identifies DTP subpopulation using HOPX to develop targeted therapy resistance in lung adenocarcinoma
Epigenomic analysis identifies DTP subpopulation using HOPX to develop targeted therapy resistance in lung adenocarcinoma Open
View article: Functional genomics pipeline identifies CRL4 inhibition for the treatment of ovarian cancer
Functional genomics pipeline identifies CRL4 inhibition for the treatment of ovarian cancer Open
Background The goal of precision oncology is to find effective therapeutics for every patient. Through the inclusion of emerging therapeutics in a high‐throughput drug screening platform, our functional genomics pipeline inverts the common…
View article: HLA-E and NKG2A Mediate Resistance to BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer
HLA-E and NKG2A Mediate Resistance to BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer Open
SUMMARY Bacillus Calmette-Guérin (BCG) is the first-line therapy for high-grade non-muscle-invasive bladder cancer (NMIBC), yet many patients experience recurrence due to immune evasion. We identify HLA-E and NKG2A as mediators of adaptive…
View article: Heterogeneity in tumor-intrinsic sensitivity to interferon gamma stimulation
Heterogeneity in tumor-intrinsic sensitivity to interferon gamma stimulation Open
Interferon gamma (IFNg) drives resistance to PD1-targeting immunotherapies by altering the tumor-intrinsic immune phenome associated with the upregulation of inhibitory ligands and immunosuppressive mediators. Major bottleneck to improving…
View article: Multiscale protein networks systematically identify aberrant protein interactions and oncogenic regulators in seven cancer types
Multiscale protein networks systematically identify aberrant protein interactions and oncogenic regulators in seven cancer types Open
View article: Epinephrine inhibits PI3Kα via the Hippo kinases
Epinephrine inhibits PI3Kα via the Hippo kinases Open
The phosphoinositide 3-kinase p110α is an essential mediator of insulin signaling and glucose homeostasis. We interrogated the human serine, threonine, and tyrosine kinome to search for novel regulators of p110α and found that the Hippo ki…
View article: Author Correction: A local tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma
Author Correction: A local tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma Open
View article: Supplementary Table 5 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
Supplementary Table 5 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine Open
Supplementary Table 5. Patient B Single and buparlisib Combination High Throughput Drug Screen.
View article: Supplementary Table Legends from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
Supplementary Table Legends from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine Open
Supplementary Table Legends
View article: Supplementary Table 7 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
Supplementary Table 7 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine Open
Supplementary Table 7. Patient D SINGLE and afatinib COMBINATION High Throughput Drug Screen.
View article: Data from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
Data from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine Open
Precision medicine is an approach that takes into account the influence of individuals' genes, environment, and lifestyle exposures to tailor interventions. Here, we describe the development of a robust precision cancer care platform that …
View article: Supplementary Table 6 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
Supplementary Table 6 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine Open
Supplementary Table 6. Patient C Single and trametinib Combination High Throughput Drug Screen.
View article: Supplementary Table Legends from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
Supplementary Table Legends from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine Open
Supplementary Table Legends
View article: Supplementary Table 5 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
Supplementary Table 5 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine Open
Supplementary Table 5. Patient B Single and buparlisib Combination High Throughput Drug Screen.
View article: Supplementary Table 1 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
Supplementary Table 1 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine Open
Supplementary Table 1. Genomic analysis of 15 patients.
View article: Supplementary Table 6 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
Supplementary Table 6 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine Open
Supplementary Table 6. Patient C Single and trametinib Combination High Throughput Drug Screen.
View article: Supplementary Table 1 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
Supplementary Table 1 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine Open
Supplementary Table 1. Genomic analysis of 15 patients.
View article: Supplementary Table 2 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
Supplementary Table 2 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine Open
Supplementary Table 2. Drug Library Concentrations.
View article: Supplementary Table 4 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
Supplementary Table 4 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine Open
Supplementary Table 4. Patient A Single and vorinostat COMBINATION High Throughput Drug Screen.
View article: Supplementary Table 3 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
Supplementary Table 3 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine Open
Supplementary Table 3. Patient A single and duparlisib combination high throughout drug screen.
View article: Supplementary Table 4 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
Supplementary Table 4 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine Open
Supplementary Table 4. Patient A Single and vorinostat COMBINATION High Throughput Drug Screen.
View article: Supplementary Figures 1 - 6 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
Supplementary Figures 1 - 6 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine Open
Supplementary Figures 1 - 6
View article: Supplementary Figures 1 - 6 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
Supplementary Figures 1 - 6 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine Open
Supplementary Figures 1 - 6
View article: Supplementary Table 2 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
Supplementary Table 2 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine Open
Supplementary Table 2. Drug Library Concentrations.
View article: Supplementary Table 3 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
Supplementary Table 3 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine Open
Supplementary Table 3. Patient A single and duparlisib combination high throughout drug screen.
View article: Supplementary Table 7 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
Supplementary Table 7 from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine Open
Supplementary Table 7. Patient D SINGLE and afatinib COMBINATION High Throughput Drug Screen.
View article: Data from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
Data from Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine Open
Precision medicine is an approach that takes into account the influence of individuals' genes, environment, and lifestyle exposures to tailor interventions. Here, we describe the development of a robust precision cancer care platform that …
View article: Data from 3-Phosphoinositide–Dependent Kinase 1 Potentiates Upstream Lesions on the Phosphatidylinositol 3-Kinase Pathway in Breast Carcinoma
Data from 3-Phosphoinositide–Dependent Kinase 1 Potentiates Upstream Lesions on the Phosphatidylinositol 3-Kinase Pathway in Breast Carcinoma Open
Lesions of ERBB2, PTEN, and PIK3CA activate the phosphatidylinositol 3-kinase (PI3K) pathway during cancer development by increasing levels of phosphatidylinositol-3,4,5-triphosphate (PIP3). 3-Phosphoinositide-dependent kinase 1…